Table 3 Univariable and multivariable analysis of the clinical factors predictive of HCC development and all-cause mortality.

From: Differential Effect of HCV Eradication and Fibrosis Grade on Hepatocellular Carcinoma and All-cause Mortality

 

HCC development

All-cause mortality

Univariable analysis

Multivariable analysis

Univariable analysis

Multivariable analysis

Hazard ratio (95% CI)

P value

Adjusted hazard ratio (95% CI)

P value

Hazard ratio (95% CI)

P value

Adjusted hazard ratio (95% CI)

P value

Age, y

1.058 (1.035–1.082)

<0.001

  

1.064 (1.034–1.095)

<0.001

  

Male

2.282 (1.471–3.541)

<0.001

2.261 (1.268–4.032)

0.009

1.898 (1.064–3.387)

0.03

  

Genotype

 

0.06

   

0.09

  

  1

1 [Reference]

   

1 [Reference]

   

  2

0.572 (0.359–0.913)

0.02

  

0.687 (0.371–1.274)

0.23

  

Other

0.469 (0.065–3.396)

0.45

  

2.567 (0.773–8.525)

0.12

  

Platelet count, ×109/L

0.983 (0.979–0.988)

<0.001

  

0.99 (0.984–0.996)

<0.001

  

Albumin, g/dL

0.157 (0.093–0.263)

<0.001

  

0.109 (0.054–0.219)

<0.001

0.144 (0.065–0.319)

<0.001

Total bilirubin, mg/dL

2.766 (1.733–4.414)

<0.001

2.051 (1.122–3.75)

0.03

2.758 (1.432–5.311)

0.002

3.483 (1.657–7.318)

<0.001

ALT, IU/L

0.997 (0.994–1.001)

0.12

  

0.996 (0.991–1.001)

0.11

  

AST, IU/L

1.001 (0.999–1.004)

0.24

  

1 (0.994–1.005)

0.95

  

GGT, IU/L

1.003 (1.001–1.005)

<0.001

1.002 (1–1.005)

0.047

1.002 (0.999–1.005)

0.15

  

INR

5.937 (2.313–15.235)

<0.001

6.331 (1.409–28.454)

0.01

12.666 (4.633–34.628)

<0.001

  

AFP, ng/mL

1 (0.999–1.001)

0.99

  

1.000 (0.999–1.001)

0.95

  

HCV RNA, log10 IU/ml

0.892 (0.707–1.126)

0.34

  

0.906 (0.663–1.239)

0.54

  

APRI

 

<0.001

   

0.21

  

  <0.5

1 [Reference]

   

1 [Reference]

   

  ≥0.5 to <1.5

1.91 (0.816–4.473)

0.14

  

1.569 (0.608–4.047)

0.35

  

  ≥1.5

5.133 (2.286–11.525)

<0.001

  

2.278 (0.882–5.883)

0.09

  

FIB-4

 

<0.001

 

0.002

 

0.02

  

  <1.45

1 [Reference]

 

1 [Reference]

 

1 [Reference]

   

  ≥1.45 to <3.25

4.377 (1.011–18.951)

0.05

2.403 (0.54–10.692)

0.25

8.155 (1.072–62.021)

0.04

  

  ≥3.25

14.057 (3.413–57.896)

<0.001

5.814 (1.368–24.709)

0.02

13.861 (1.864–103.07)

0.01

  

Diabetes mellitus

  No

1 [Reference]

   

1 [Reference]

   

  Yes

2.008 (1.244–3.241)

0.004

  

1.79 (0.931–3.44)

0.08

  

Hypertension

  No

1 [Reference]

   

1 [Reference]

   

  Yes

1.256 (0.746–2.115)

0.39

  

1.21 (0.585–2.499)

0.61

  

Treatment

 

<0.001

 

<0.001

 

<0.001

 

<0.001

Untreated

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

1 [Reference]

 

Treated wihout SVR

0.733 (0.385–1.397)

0.35

0.658 (0.313–1.383)

0.27

0.314 (0.097–1.016)

0.05

0.099 (0.013–0.731)

0.02

Treated wih SVR

0.304 (0.172–0.537)

<0.001

0.165 (0.077–0.35)

<0.001

0.173 (0.068–0.44)

<0.001

0.146 (0.05–0.424)

<0.001

  1. P values were determined using Cox proportional hazards regression models. P < 0.05 indicated a significant difference.
  2. Variables in the multivariable analysis were selected using stepwise regression with the forward selection method.
Back to article page